Antibody-targeted radiation cancer therapy
TLDR
The development and use of radionuclide-bearing monoclonal antibody therapies are discussed, with a focus on radiolabelled monOClonal antibodies that have been evaluated in clinical trials.Abstract:
Several monoclonal antibodies are now approved for cancer therapy, such as rituximab, an anti-CD20 monoclonal antibody for the treatment of B-cell non-Hodgkin's lymphoma Such 'naked' antibodies can recruit the body's immune effector mechanisms to kill cells expressing the target of the antibody In recent years, the linking of radionuclides to antibodies to either augment inherent activity or to exploit the specific targeting properties of monoclonal antibodies has been a major area of development Two radionuclide-bearing monoclonal antibody therapies have recently been approved by the US FDA, and several more are in clinical trials Here, we discuss the development and use of radiolabelled monoclonal antibody therapies, with a focus on radiolabelled monoclonal antibodies that have been evaluated in clinical trialsread more
Citations
More filters
Journal ArticleDOI
Polymer conjugates as anticancer nanomedicines
TL;DR: There is growing optimism that ever more sophisticated polymer-based vectors will be a signficant addition to the armoury currently used for cancer therapy.
Journal ArticleDOI
Arming antibodies: prospects and challenges for immunoconjugates
Anna M. Wu,Peter D. Senter +1 more
TL;DR: For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs.
Journal ArticleDOI
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium and Zirconium for PET and SPECT Imaging of Disease
TL;DR: SPECT and PET technology has been around for decades, but its use remained limited because of the limited availability of relevant isotopes which had to be produced in nuclear reactors or particle accelerators, but the introduction of the small biomedical cyclotron, the self-contained radionuclide generator and the dedicated small animal or clinical SPECT andPET scanners to hospitals and research facilities has increased the demand for SPect and PET isotopes.
Journal ArticleDOI
Antibody targeted drugs as cancer therapeutics
TL;DR: Recent preclinical and clinical data for antibody–drug conjugates and fusion proteins with a special focus on drug components that exert their antitumour effects through normal biological processes are discussed.
Journal ArticleDOI
Development trends for monoclonal antibody cancer therapeutics
TL;DR: Trends in the clinical development and regulatory approval of monoclonal antibodies for cancer since 1980 are overviewed with the aim of informing future research and development for this class of therapeutics.
References
More filters
Journal ArticleDOI
Continuous cultures of fused cells secreting antibody of predefined specificity
G Köhler,C. Milstein +1 more
TL;DR: The derivation of a number of tissue culture cell lines which secrete anti-sheep red blood cell (SRBC) antibodies is described here, made by fusion of a mouse myeloma and mouse spleen cells from an immunised donor.
Journal Article
The pilot study.
TL;DR: A randomized controlled experiment is designed to test whether access to affordable day care (in the form of subsidies, for example) would incentivize Saudi mothers to search actively for employment and to remain employed once they are hired.
Journal ArticleDOI
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
TL;DR: It is demonstrated that Fc-receptor-dependent mechanisms contribute substantially to the action of cytotoxic antibodies against tumors and indicate that an optimal antibody against tumors would bind preferentially to activation Fc receptors and minimally to the inhibitory partner FcγRIIB.
Journal ArticleDOI
Monoclonal antibody-mediated tumor regression by induction of apoptosis
B. C. Trauth,C. Klas,Anke M.J. Peters,Siegfried Matzku,Peter Möller,Werner Falk,Klaus-Michael Debatin,Peter H. Krammer +7 more
TL;DR: Histological thin sections of the regressing tumor showed that anti-APO-1 was able to induce apoptosis in vivo, suggesting induction of apoptosis as a consequence of a signal mediated through cell surface molecules like APO- 1 may be a useful therapeutic approach in treatment of malignancy.
Journal ArticleDOI
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
David G. Maloney,Antonio J. Grillo-Lopez,Christine A. White,David Bodkin,Russell J. Schilder,James A. Neidhart,Nalini Janakiraman,Kenneth A. Foon,Tina Marie Liles,Brian Dallaire,Ken Wey,Ivor Royston,Thomas A. Davis,Ronald Levy +13 more
TL;DR: Likelihood of tumor response was associated with a follicular histology, with the ability to sustain a high serum level of antibody after the first infusion, and with a longer duration of remission to prior chemotherapy, and IDEC-C2B8 has a better safety profile.
Related Papers (5)
Continuous cultures of fused cells secreting antibody of predefined specificity
G Köhler,C. Milstein +1 more
Targeted α particle immunotherapy for myeloid leukemia
Joseph G. Jurcic,Steven M. Larson,Steven M. Larson,George Sgouros,George Sgouros,Michael R. McDevitt,Michael R. McDevitt,Ronald D. Finn,Ronald D. Finn,Chaitanya R. Divgi,Chaitanya R. Divgi,Åse Ballangrud,Åse Ballangrud,Klaus A. Hamacher,Klaus A. Hamacher,Dangshe Ma,Dangshe Ma,John Humm,John Humm,Martin W. Brechbiel,Martin W. Brechbiel,Roger Molinet,Roger Molinet,David A. Scheinberg,David A. Scheinberg +24 more